Johnson & Johnson
JNJ
Updated: 22/09/2026, 22:09:03
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $269.31
- Market cap
- $649.01B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Joaquin Duato
- Employees
- 141,700
- IPO date
- 02/01/1962
- Beta
- 0.235
- Last dividend
- $0.00
- Day range
- $265.04 – $270.10
- 52-week range
- $174.83 – $281.07
- 1-day performance
- -0.06%
- 1-year performance
- 54.04%
- Current drawdown (1Y)
- -4.18%
- CIK
- 0000200406
- CUSIP
- 478160104
- ISIN
- US4781601046
- Created
- 07/12/2025, 04:53:05
- Last update
- 22/09/2026, 22:09:03
Track Johnson & Johnson with an AI analyst
See which prediction-market events move JNJ, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
Business Wire • STOCK • 15/06/2026, 08:00:00
A $650,000 Portfolio That Could Send You to the Super Bowl Every Year
247 Wallst • STOCK • 13/06/2026, 12:22:44
The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I'm Loading Up on Anyway
24/7 Wall Street • STOCK • 11/06/2026, 15:08:00
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
Business Wire • STOCK • 11/06/2026, 09:45:00
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
PRNewsWire • STOCK • 11/06/2026, 04:03:00
I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow
24/7 Wall Street • STOCK • 10/06/2026, 14:39:11
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
Business Wire • STOCK • 10/06/2026, 13:22:00
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
24/7 Wall Street • STOCK • 10/06/2026, 13:20:58
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
WSJ • STOCK • 10/06/2026, 08:20:00
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
Zacks Investment Research • STOCK • 09/06/2026, 14:20:25
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
Zacks Investment Research • STOCK • 09/06/2026, 14:06:16
Will Johnson & Johnson Stock Hit $300 This Year?
24/7 Wall Street • STOCK • 09/06/2026, 12:06:47